肿瘤领域中药-药物相互作用的真实世界数据:药物流行病学研究范围综述
汇总显示45.4%的中药使用者存在HDI风险,多数真实世界数据识别的相互作用未导致不良临床结局。
要点
- 肿瘤患者联用中药普遍,45.4%的中药使用者存在HDI风险。
- 他莫昔芬、环磷酰胺和紫杉醇是研究最多的相互作用药物。
- 多数真实世界数据识别的HDI未导致不良临床结局。
核心结论
- 肿瘤患者中药使用日益普遍,对HDI的药物流行病学研究需求高。
- 真实世界数据中45.4%的中药使用者存在HDI风险。
- 多数真实世界数据识别的相互作用未导致不良临床结局。
研究设计与样本
- 范围综述,检索九个中英文数据库从建库至2021年5月,并补充灰色文献与手工检索。
- 回顾性队列研究5项(17.9%),前瞻性队列研究2项(7.1%)。
主要发现
- 研究最多的三种肿瘤药物为他莫昔芬(11项,39.3%)、环磷酰胺(6项,21.4%)和紫杉醇(6项,21.4%)。
- 横断面研究多利用三级数据库和原始文献检索识别潜在HDI。
- 前瞻性和回顾性研究主要调查实际临床结局,如不良事件和第二原发肿瘤。
- 汇总分析显示45.4%的中药使用者存在HDI风险。
关键数值与推荐
- 45.4%的中药使用者存在HDI风险,基于纳入研究数据合并估计。
临床怎么用
- 肿瘤患者联用中药时,应关注他莫昔芬、环磷酰胺和紫杉醇的潜在HDI。
- 真实世界数据提示多数HDI未导致不良临床结局,但仍需个体化评估。
局限性
- 纳入研究常见局限性包括样本量有限。
- 缺乏中药使用数据和HDI详细信息。
- 缺乏HDI证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The concurrent use of conventional drugs and herbal medicines is becoming popular among patients with cancer. However, the potential risk of herb-drug interactions (HDI) remains under-addressed in the literature. Previous reviews have mainly focused on the prevalence of interactions, with less attention paid to the methods used by pharmacoepidemiological studies on evaluating HDI. This scoping review aims to summarize the existing pharmacoepidemiological studies that evaluate HDI using real-world data and to identify gaps to be addressed in future research. METHODS: A comprehensive search was performed in nine English- and Chinese-language databases from their inception to May 2021. Gray literature and manual searches were conducted to identify additional studies. The recommended components of the pharmacoepidemiological studies and key findings related to HDI were summarized. The proportion (%) of patients with cancer at risk of HDI was estimated by combining data from eligible studies. RESULTS: Twenty-eight studies were included in the review. More than half of these studies were cross-sectional studies (n = 18, 64.3%), followed by retrospective cohort studies (n = 5, 17.9%) and prospective cohort studies (n = 2, 7.1%). The three cancer drugs most commonly studied for their interaction potential with herbs were tamoxifen (n = 11, 39.3%), cyclophosphamide (n = 6, 21.4%), and paclitaxel (n = 6, 21.4%). Most cross-sectional studies identified potential HDI using tertiary databases and primary literature searches. Conversely, prospective and retrospective studies mainly investigated actual clinical outcomes, such as adverse events and secondary cancer occurrences. Most interaction outcomes identified using real-world data did not lead to negative clinical consequences. Collectively, 45.4% of herbal medicine users of the included studies were found to be at risk of HDI. We infer from this review that the common limitations of these studies were limited sample size, lack of data on herbal medicine use and details of HDI, and lack of evidence of HDI. Based on the study limitations, several recommendations to enrich the data sources and optimize the study designs were proposed. CONCLUSIONS: There is a high demand for pharmacoepidemiological research on HDI, considering the increasing popularity of herbal medicine among patients with cancer. It is anticipated that emerging real-world data in this field can guide the development of safe and effective approaches to integrative oncology.
引用
- Lam CS, Koon HK, Ma CT, et al. Real-world data on herb-drug interactions in oncology: A scoping review of pharmacoepidemiological studies. Phytomedicine. 2022. PMID: 35716539. doi:10.1016/j.phymed.2022.154247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。